Fingolimod (FTY720) HCl

Catalog No.S5002

For research use only.

Fingolimod (FTY720) HCl is a S1P antagonist with IC50 of 0.033 nM in K562, and NK cells.

Fingolimod (FTY720) HCl Chemical Structure

CAS No. 162359-56-0

Selleck's Fingolimod (FTY720) HCl has been cited by 96 publications

Purity & Quality Control

Choose Selective S1P Receptor Inhibitors

Other S1P Receptor Products

Biological Activity

Description Fingolimod (FTY720) HCl is a S1P antagonist with IC50 of 0.033 nM in K562, and NK cells.
Targets
S1P receptor [1]
(K562, NK cells )
0.033 nM
In vitro

The inhibitory effect of S1P is revered by various concentrations of FTY720, with IC50 effect of 173 nM. In addition, FTY720 (10 nM) alone exerts no effect on the expression of co-stimulatory molecules. FTY720 reverses the increased expression of HLA-I induced by S1P for both the percentages of cells and the MFI, upon comparing the effect of S1P to the effect of combining S1P with FTY720. [1] Medium and high-dose FTY720-P also enhances the levels of TGF-β1. TGF-β1 and Foxp3 mRNA expression are upregulated in the high-dose FTY720-P group. The proliferation of effector T cells is suppressed significantly in the medium and high-dose FTY720-P group at a Treg/Teff cell ratio of 1:1. At a ratio of 1:1, the proliferation of effector T cells is also suppressed in the high-dose FTY720 group. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human U2OS cells MljvSpVv[3Srb36gZZN{[Xl? NFr3ZVZC\2:waYP0JIFkfGm4aYT5JIF1KGi3bXHuJHMyWDFicnXj[ZB1d3JiZYjwdoV{e2WmIHnuJIh2dWGwIGWyU3Mh[2WubIOgZ48u\XiycnXzd4lv\yCnR1\QJIF{e2W|c3XkJIF{KHKnY3XweI9zKGmwdHXycoFtcXqjdHnvckBqdnSxIHP5eI9xdGG|bTD1d4lv\yCKb3XjbJN1KGS7ZTDzeIFqdmmwZzygSWM2OD1yLkCwNkDPxE1w MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjFyNEG0OEc,OjJzMESxOFQ9N2F-
human PC3 cells NE\LeGREgXSxdH;4bYPDqGG|c3H5 NWnZNnlDPzJiaB?= M3O1OmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHBEOyClZXzsd{Bi\nSncjC3NkBpenNiYomgeol1[WxiZInlJIV5[2y3c3nvck9ndG:5IHP5eI9u\XS{aXOgZY5idHm|aYOsJGlEPTB;OT64JO69VS5? M{C0SVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MkezOlMzLz5{NEK3N|Y{OjxxYU6=
human NALM6 cells NFrXUVBEgXSxdH;4bYPDqGG|c3H5 M{TaV|czKGh? NVjlUWY1S3m2b4TvfIlkcXS7IHHnZYlve3RiUHitcoVo[XSrdnWgbJVu[W5iTlHMUVYh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7II\peIFtKGS7ZTDlfINtfXOrb36v[oxwfyCleYTvcYV1emmlIHHuZYx6e2m|LDDJR|UxRTlwNjFOwG0v NH3oO5I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK3N|Y{Oid-MkSyO|M3OzJ:L3G+
human CCRF-CEM cells M4\tNGN6fG:2b4jpZ:Kh[XO|YYm= MmnNO|IhcA>? M{X4S2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KFCqLX7l[4F1cX[nIHj1cYFvKEOFUl[tR2VOKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTD2bZRidCCmeXWg[ZhkdHW|aX;uM4Ztd3diY4n0c41mfHKrYzDhcoFtgXOrczygTWM2OD14Lkig{txONg>? M2Pmd|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MkezOlMzLz5{NEK3N|Y{OjxxYU6=
human SUP-B15 cells MkK5R5l1d3SxeHnjxsBie3OjeR?= M4nle|czKGh? MlKzR5l1d3SxeHnjbZR6KGGpYXnud5QhWGhvcH;zbZRqfmViaIXtZY4hW1WSLVKxOUBk\WyuczDh[pRmeiB5MjDodpMh[nlidnn0ZYwh\HmnIHX4Z4x2e2mxbj;mcI94KGO7dH;t[ZRzcWNiYX7hcJl{cXNuIFnDOVA:Pi56IN88UU4> MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ5M{[zNkc,OjR{N{O2N|I9N2F-
human DU145 cells M33BXWN6fG:2b4jpZ:Kh[XO|YYm= NVXUXmEzPzJiaB?= NWGxUnNIS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hTFVzNEWgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KH[rdHHsJIR6\SCneHPseZNqd25xZnzve{BkgXSxbXX0dolkKGGwYXz5d4l{NCCLQ{WwQVYvPSEQvF2u NYHoZ5JmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyO|M3OzJpPkK0Nlc{PjN{PD;hQi=>
human BV173 cells MmD5R5l1d3SxeHnjxsBie3OjeR?= NYXxW41YPzJiaB?= Ml75R5l1d3SxeHnjbZR6KGGpYXnud5QhWGhvcH;zbZRqfmViaIXtZY4hSlZzN{OgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KH[rdHHsJIR6\SCneHPseZNqd25xZnzve{BkgXSxbXX0dolkKGGwYXz5d4l{NCCLQ{WwQVYvOyEQvF2u MkTiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{N{O2N|IoRjJ2MkezOlMzRC:jPh?=
human BLIN-1 cells NWTrNlg4S3m2b4TvfIlkyqCjc4PhfS=> NHXpZoE4OiCq NHXwU3NEgXSxdH;4bYNqfHliYXfhbY5{fCCSaD3u[YdifGm4ZTDoeY1idiCETFnOMVEh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7II\peIFtKGS7ZTDlfINtfXOrb36v[oxwfyCleYTvcYV1emmlIHHuZYx6e2m|LDDJR|UxRTVwNTFOwG0v MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ5M{[zNkc,OjR{N{O2N|I9N2F-
mouse bone marrow cells MYTDfZRwfG:6aXRCpIF{e2G7 NYnOe3hMPzJiaB?= M2fHWWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KEKFUj3BRmwh\nW|aX;uJJBzd3SnaX6gNVkxKGW6cILld5NqdmdibX;1d4Uh[m:wZTDtZZJzd3diY3XscJMh[W[2ZYKgO|IhcHK|IHL5JJZqfGGuIHT5[UBmgGOudYPpc44w\myxdzDjfZRwdWW2cnnjJIFv[Wy7c3nzMEBKSzVyPUOuN{DPxE1w M1KxdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MkezOlMzLz5{NEK3N|Y{OjxxYU6=
Sf9 insect cells MoTsSpVv[3Srb36gZZN{[Xl? Mkf0NUBp Mom4TY5pcWKrdHnvckBw\iCqdX3hckBz\WOxbXLpcoFvfCCVMWDMJEg3OiC2bzC1OlgqKGW6cILld5Nm\CCrbjDT[lkhcW6|ZXP0JINmdGy|IIXzbY5oKFNzUDDhd{B{fWK|dILheIUh[W[2ZYKgNUBpeg>? MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDhyOUixOEc,OjR6MEm4NVQ9N2F-
mouse MN9D cells MVjGeY5kfGmxbjDhd5NigQ>? NGrmRoI2KM7:TR?= MUPJcoR2[3Srb36gc4YhWFB{QTDjZZRidHm2aXOgd5VjfW6rdDDhZ5Rqfmm2eTDpckBud3W|ZTDNUllFKGOnbHzzJIF{e2W|c3XkJIF{KHCqb4PwbIF1\SCuZY\lcEBifCB3IIXN NUnSbHRIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwOVAyPjVpPkK1NFUxOTZ3PD;hQi=>
rat PC12 cells NXzHfmN5TnWwY4Tpc44h[XO|YYm= Mln0OUDPxE1? MoG2N|AhfG9iMUKwJI1qdnN? MmPNTY5lfWO2aX;uJI9nKFCSMlGgZ4F1[Wy7dHnjJJN2[nWwaYSgZYN1cX[rdImgbY4hemG2IGDDNVIh[2WubIOgZZN{\XO|ZXSgZZMheGixc4DoZZRmKGyndnXsJIF1KDVidV2gcYVie3W{ZXSgN|AhfG9iMUKwJI1qdnNw MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTB3MEG2OUc,OjVyNUCxOlU9N2F-
mouse MN9D cells MXfGeY5kfGmxbjDhd5NigQ>? MYmwMlE3KM7:TR?= NYHJZopLOjRiaB?= NF3UR2JP\XW{b4Dyc5Rm[3SrdnWgZYN1cX[rdImgbY4hdW:3c3WgUW46TCClZXzsd{Bie3Onc4Pl[EBieyC|dHnteYxifGmxbjDv[kBDTE6IIHX4dJJme3Orb36gZZQhOC5zNjD1UUBi\nSncjCyOEBpenN? MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTB3MEG2OUc,OjVyNUCxOlU9N2F-
mouse MN9D cells MUPGeY5kfGmxbjDhd5NigQ>? M2LySFAvOTZizszN NWXXO3llPzJiaB?= NHXhcoVP\XW{b4Dyc5Rm[3SrdnWgZYN1cX[rdImgbY4hdW:3c3WgUW46TCClZXzsd{Bie3Onc4Pl[EBieyCkbH;jb4lv\yCxZjDUUmYu[WyyaHGgZZN{d2OrYYTl[EB1d3irY3n0fUBifCByLkG2JJVOKGGodHXyJFczKGi{czDifUBVenmyYX6gZox2\SC|dHHpcolv\y5? M{D6TVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEWwNVY2Lz5{NUC1NFE3PTxxYU6=
CHO MlT2SpVv[3Srb36gZZN{[Xl? Mmj0SIl{eGyjY3Xt[Y51KG:oIGuzN3Bee3CqaX7nc5NqdmViMTDwbI9{eGijdHWg[pJwdSCqdX3hckBUOVBzIILlZ4VxfG:{IHX4dJJme3OnZDDpckBEUE9iY3XscJMtKEmFNUC9NE45PM7:TT6= NGTaNmM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNU[xOVUyOyd-MUW2NVU2OTN:L3G+
CHO MlLYSpVv[3Srb36gZZN{[Xl? NWTIOY1PTGm|cHzhZ4Vu\W62IH;mJHs{O1Cfc4DobY5od3OrbnWgNUBxcG:|cHjheIUh\nKxbTDoeY1idiCVMWC1JJJm[2WydH;yJIV5eHKnc4Pl[EBqdiCFSF:gZ4VtdHNuIFnDOVA:Oi5zzszNMi=> M1zOdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF3NkG1OVE{Lz5zNU[xOVUyOzxxYU6=
Jurkat MYXGeY5kfGmxbjDhd5NigQ>? MVSxPEBpenN? M3\sN3JmfmW{c3HsJI9nKGmwaHnibZRqd25ib3[gcYl1d2Oqb37kdolidCCodX7jeIlwdiCrbjDoeY1idiCMdYLrZZQh[2WubIOgZYZ1\XJiMUigbJJ{KGmwIIDy[ZNmdmOnIH;mJHouXkGGLX\tby=> MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzRyMEW1OUc,OTd2MEC1OVU9N2F-
T-cells M2S0W2Z2dmO2aX;uJIF{e2G7 MYS5OkBpenN? MlvjTY1ufW6xc4XwdJJme3OrdnWgZYN1cX[rdImgbY4hSkGOQj;jM2M2P0KOL{[gcY92e2ViVDDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKGGubH;hcpRq\2WwLXnu[JVk\WRiY3XscEBxem:uaX\ldoF1cW:wIHHmeIVzKDl4IHjyd{BjgSCvZXHzeZJqdmdiW{PIYZRpgW2rZHnu[UB2eHSja3WgZpkhdWm6ZXSgcJlueGixY4n0[UBz\WGldHnvckBie3OjeTygTWM2OD1yLkCwOlHPxE1w MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTR3NkWyOEc,OjF2NU[1NlQ9N2F-
SK-BR-3 MVXBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? M3SzWVc5KGi{cx?= NHn0WllCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGPLMWJTNTNiY3XscJMh[XO|ZYPz[YQh[XNiZ4Lve5RpKGmwaHnibZRqd25iYX\0[ZIhPzhiaILzJIJ6KFeVVD2xJIF{e2G7LDDJR|UxRTYQvF2u M2PMPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNEW2OVI1Lz5{MUS1OlUzPDxxYU6=
MDA-MB-231 MkXGRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? MmPGO|ghcHK| NI\MdppCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3ERU1OSi1{M{GgZ4VtdHNiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiN{igbJJ{KGK7IGfTWE0yKGG|c3H5MEBKSzVyPUZOwG0v Mn7PQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF2NU[1NlQoRjJzNEW2OVI1RC:jPh?=
HCT116 NIW2XZdCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= MnXKO|ghcHK| MWLBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiFVEGxOkBk\WyuczDhd5Nme3OnZDDhd{Boem:5dHigbY5pcWKrdHnvckBi\nSncjC3PEBpenNiYomgW3NVNTFiYYPzZZktKEmFNUC9Oe69VS5? MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTR3NkWyOEc,OjF2NU[1NlQ9N2F-
SW620 M3T5c2FvfGmycn;sbYZmemG2aY\lJIF{e2G7 NGriOYw4QCCqcoO= MkO1RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCVV{[yNEBk\WyuczDhd5Nme3OnZDDhd{Boem:5dHigbY5pcWKrdHnvckBi\nSncjC3PEBpenNiYomgW3NVNTFiYYPzZZktKEmFNUC9Oe69VS5? M4D0OVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNEW2OVI1Lz5{MUS1OlUzPDxxYU6=
MCF7 NVrz[IVNSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= NHL2TYM4QCCqcoO= MV3BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2FRkegZ4VtdHNiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiN{igbJJ{KGK7IGfTWE0yKGG|c3H5MEBKSzVyPUZOwG0v NG\CVo89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUS1OlUzPCd-MkG0OVY2OjR:L3G+
LNCAP-AI MoPiRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? MoXWO|ghcHK| MX3BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDoeY1idiCOTlPBVE1CUSClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghcW6qaXLpeIlwdiCjZoTldkA4QCCqcoOgZpkhX1OWLUGgZZN{[XluIFnDOVA:Pc7:TT6= M2nzdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNEW2OVI1Lz5{MUS1OlUzPDxxYU6=
MGC803 MUDBcpRqfHWvb4KgZZN{[Xl? MnWxNVAhdWdxa3e= MUOyNEBl[Xm| MVjBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6|dDDoeY1idiCPR1O4NFMh[2WubIOgfIVvd2e{YX\0[YQhcW5iboXk[UBud3W|ZTDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIIT1cY9zKGe{b4f0bEBifCBzMDDt[{9s\yCob4KgNlAh\GG7cx?= NFH1[VA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUS1OlUzPCd-MkG0OVY2OjR:L3G+
U2OS NXnkR|A6TnWwY4Tpc44h[XO|YYm= M3HtVFE5KGi{cx?= NYnPenM5SWexbnnzeEBi[3Srdnn0fUBifCCqdX3hckBUOVBzIILlZ4VxfG:{IHX4dJJme3OnZDDpckBGTEdzLXLsZUBWOk:VIHPlcIx{KGmwY4XiZZRm\CCob4KgNVghcHK|IIDybY9zKHSxIFflcmJt[XqncjDzeYJ{fHKjdHWgZYRlcXSrb36gZpkh[mW2YT3hdpJme3SrbjDy[YNzfWm2bXXueEBie3OjeTygSWM2OD1yLkCwO|LPxE1w MmG1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ4OEe0PFcoRjJ4Nki3OFg4RC:jPh?=
FL5.12A Mnf5R5l1d3SxeHnjbZR6KGG|c3H5 MlPLOFghcHK| NUC5d2E1S3m2b4TvfIlkcXS7IHHnZYlve3RibX;1d4UhTkx3LkGyRUBk\WyuczDh[pRmeiB2ODDodpMh[nliRFHQTUB{fGGrbnnu[{1j[XOnZDDmcI94KGO7dH;t[ZRzcWNiYX7hcJl{cXNuIFnDOVA:Oi52zszNMi=> NIjwS5I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{S3OVU{PCd-Mke0O|U2OzR:L3G+
SH-SY5Y MUTDfZRwfG:6aXPpeJkh[XO|YYm= NVTwfYhsOjRiaILz M{jRXGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHNJNVO\NWmgZ4VtdHNibXXhd5Vz\WRiYX\0[ZIhOjRiaILzJIJ6KGO{eYP0ZYwufmmxbHX0JJN1[WmwaX7nJIJie2WmIHHzd4F6NCCHQ{GwQVAvPTUQvF2u NUi5[o96RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke5NVMyOTVpPkK3PVE{OTF3PD;hQi=>
SK-N-SH MmnXR5l1d3SxeHnjbZR6KGG|c3H5 MUCyOEBpenN? NEPhW|ZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBUUy2QLWPIJINmdGy|IH3lZZN2emWmIHHmeIVzKDJ2IHjyd{BjgSClconzeIFtNX[rb3zleEB{fGGrbnnu[{Bj[XOnZDDhd5NigSxiRVOxNF0xNjV3zszNMi=> M4\YXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OUGzNVE2Lz5{N{mxN|EyPTxxYU6=
U118MG NWfETVliS3m2b4TvfIlkcXS7IHHzd4F6 NYHIblNQOjRiaILz NXPOOppCS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hXTFzOF3HJINmdGy|IH3lZZN2emWmIHHmeIVzKDJ2IHjyd{BjgSClconzeIFtNX[rb3zleEB{fGGrbnnu[{Bj[XOnZDDhd5NigSxiRVOxNF0xNjZzzszNMi=> NUXETWdURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke5NVMyOTVpPkK3PVE{OTF3PD;hQi=>
SH-SY5Y MWXGeY5kfGmxbjDhd5NigQ>? M4n6emFod26rc4SgZYN1cX[rdImgZZQhe3CqaX7nc5NqdmVvMT3wbI9{eGijdHWgdoVk\XC2b4KgbY4hcHWvYX6gV2guW1l3WTDj[YxteyCjc4Pld5Nm\CCjczDpcoNz\WG|ZTDpckBkSU2SIHzleoVtKGG2IFXDNVAh[nliZHny[YN1KGmvbYXuc4F{e2G7 NETqR5M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{mxN|EyPSd-Mke5NVMyOTV:L3G+
U118MG M4LBdWZ2dmO2aX;uJIF{e2G7 M3;6dGFod26rc4SgZYN1cX[rdImgZZQhe3CqaX7nc5NqdmVvMT3wbI9{eGijdHWgdoVk\XC2b4KgbY4hcHWvYX6gWVEyQE2JIHPlcIx{KGG|c3Xzd4VlKGG|IHnuZ5Jm[XOnIHnuJINCVVBibHX2[Ywh[XRiRVOxNEBjgSCmaYLlZ5QhcW2vdX7vZZN{[Xl? M332S|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OUGzNVE2Lz5{N{mxN|EyPTxxYU6=
SK-N-SH NHW0PW1HfW6ldHnvckBie3OjeR?= NVT6U3FVSWexbnnzeEBi[3Srdnn0fUBifCC|cHjpcodwe2mwZT2xMZBpd3OyaHH0[UBz\WOncITvdkBpfW2jbjDTT{1PNVOKIHPlcIx{KGG|c3Xzd4VlKGG|IHnuZ5Jm[XOnIHnuJINCVVBibHX2[Ywh[XRiRVOxNEBjgSCmaYLlZ5QhcW2vdX7vZZN{[Xl? MnzFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd7MUOxNVUoRjJ5OUGzNVE2RC:jPh?=
HEK293 NEXzR2VHfW6ldHnvckBie3OjeR?= NFL0ZYsyQCCqcoO= NUDKPJd6SWexbnnzeEBi[3Srdnn0fUBifCC|cHjpcodwe2mwZT2xMZBpd3OyaHH0[UBz\WOncITvdkApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCKRVuyPVMh[2WubIOgZZN{\XO|ZXSgZZMhcW6lcnXhd4UhcW5iY1HNVEBt\X[nbDDheEBGSzFyIHHmeIVzKDF6IHjyd{BjgSCFUlWtdoV{eG:wc3n2[UBz\W6rbHzhJIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigQ>? MoDQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd7MUOxNVUoRjJ5OUGzNVE2RC:jPh?=
SJ-GBM2 MV3xTHRUKGG|c3H5 NGXJOHdyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1qtS2JOOiClZXzsdy=> MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
A673 MkPJdWhVWyCjc4PhfS=> M3PxTJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCDNkezJINmdGy| MkLWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
SK-N-MC MYLxTHRUKGG|c3H5 Mkj1dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tUWMh[2WubIO= M3XuTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
BT-37 Ml;wdWhVWyCjc4PhfS=> NUnhe2IyeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IFLUMVM4KGOnbHzz NGfiXHk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
NB-EBc1 MY\xTHRUKGG|c3H5 MmrxdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6ELVXCZ|Eh[2WubIO= NUTIRYxlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
Saos-2 MVPxTHRUKGG|c3H5 NIrmU5NyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU3Hvd{0zKGOnbHzz MkDqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
SK-N-SH NUfGWoczeUiWUzDhd5NigQ>? MXzxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0tvTj3TTEBk\Wyucx?= NIjwVpU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
NB1643 NV:xS5pKeUiWUzDhd5NigQ>? M3[zbZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCQQkG2OFMh[2WubIO= NHHIVYE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
LAN-5 MX;xTHRUKGG|c3H5 M2S0dJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCOQV6tOUBk\Wyucx?= NHvVcmo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
BT-12 NIPG[4VyUFSVIHHzd4F6 MV7xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSlRvMUKgZ4VtdHN? M{fFVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh18 NEXsU3pyUFSVIHHzd4F6 MYjxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWmhzODDj[Yxtew>? NIjQSnc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
OHS-50 MVPxTHRUKGG|c3H5 NXPDTGtDeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IF;IV{02OCClZXzsdy=> NIr5RVQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
RD NWL0TGExeUiWUzDhd5NigQ>? NVjZcIV3eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGLEJINmdGy| NFmwdZg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
MG 63 (6-TG R) M4S4UJFJXFNiYYPzZZk> MW\xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVUdiNkOgLFYuXEdiUjmgZ4VtdHN? NWqydlZVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh30 NUnGbVRReUiWUzDhd5NigQ>? M1HPepFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCUaEOwJINmdGy| NYO3S5RNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh41 MYLxTHRUKGG|c3H5 MmPkdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKqNEGgZ4VtdHN? MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
FL5.12 NWDHXJpJS3m2b4TvfIlkcXS7IHHzd4F6 NFTsbG41QCCqcoO= MmHFR5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgSmw2NjF{IHPlcIx{KGGodHXyJFQ5KGi{czDifUBFSVCLIH;yJJBzd3CrZHn1cUBqd2SrZHWgd5RicW6rbnetZoF{\WRiZnzve{BkgXSxbXX0dolkKGGwYXz5d4l{NCCLQ{WwQVIvOc7:TT6= NEH0PVM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEK5Nlg6QCd-M{CyPVI5QTh:L3G+
FL5.12 M4PyPGN6fG:2b4jpZ4l1gSCjc4PhfS=> MmjVNVAhfU1? M3fMbVMhcHK| M4HaS2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGZNPS5zMjDj[YxteyCjc4Pld5Nm\CCjczD2ZYN2d2ynIH\vdo1ifGmxbjDheEAyOCC3TTDh[pRmeiB|IHjyd{BjgSCobIXvdoV{[2WwY3WgcYlkem:|Y3;wbYMh[W6jbInzbZM> M1HldlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMkmyPFk5Lz5|MEK5Nlg6QDxxYU6=
FL5.12 M1LUXmN6fG:2b4jpZ4l1gSCjc4PhfS=> NVu3ZZJZOi53IIXN NV;M[WRTOyCqcoO= M{fmUmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGZNPS5zMjDj[YxteyCjc4Pld5Nm\CCjczD2ZYN2d2ynIH\vdo1ifGmxbjDheEAzNjVidV2gZYZ1\XJiMzDodpMh[nliZnz1c5Jme2OnbnPlJI1q[3Kxc3PvdIlkKGGwYXz5d4l{ M36xNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMkmyPFk5Lz5|MEK5Nlg6QDxxYU6=
HepG2 NEWydoNyUFSVIHHzd4F6 MmL3TIVxTzJiY3XscJMhfmmjYnnsbZR6KHGKVGOg[o9zKFqra3GgeolzfXNiaX7obYJqfG:{cx?= MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{OzJ{OUW0OUc,OzN{Mkm1OFU9N2F-
CHO NIrpSG1HfW6ldHnvckBie3OjeR?= MmS2RYdwdmm|dDDhZ5Rqfmm2eTDheEBpfW2jbjDTNXA{KHKnY3XweI9zKGW6cILld5Nm\CCrbjDDTG8h[2WubIOgZZN{\XO|ZXSgZZMhcW6lcnXhd4UhcW5iY3HsZ4l2dSCobIX4JIJ6KGGncYXvdolvNWSncnn2[YQhdHWvaX7ld4NmdmOnIHHzd4F6NCCHQ{WwQVIvPTFzOEpOwG0v MnLOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN|E1QDV2Lze+R4hGVUKOPD;hQi=>
CHO NFn0RlNHfW6ldHnvckBie3OjeR?= NIiwbW5C\2:waYP0JIFkfGm4aYT5JIF1KGi3bXHuJHMyWDVicnXj[ZB1d3JiZYjwdoV{e2WmIHnuJGNJVyClZXzsd{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDjZYxkcXWvIH\seZgh[nliYXXxeY9zcW5vZHXybZZm\CCudX3pcoV{[2WwY3WgZZN{[XluIFXDOVA:Oy5zNkKyPO69VS5? NX7jWmZzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzF2OEW0M{c,S2iHTVLMQE9iRg>?
Assay
Methods Test Index PMID
Western blot p-AKT / AKT / p-mTOR / mTOR / p-GSK3β / GSK3β / p-IKKα/β / IKKα / NF-κB / Survivin ; p-STAT3 / STAT3 / Bcl-xl / Bcl-2 / Bax ; Cyclin D1 / CDK4 / cyclin E / CDK2 / p27 / p16 28717222 25344679
Immunofluorescence NF-κB ; N-cadherin / Vimentin 28717222 25344679
Growth inhibition assay Cell viability 28717222
In vivo FTY720 is effective in Ph+ but not Ph- ALL xenografts using an early disease model. FTY720 produces a significant reduction in disease burden in the Ph+ ALL xenografts using an early disease model. Ph+ human ALL xenografts responds to FTY720 with an 80 % reduction in overall disease if treatment has been initiated early on. In contrast, treatment of mice with FTY720 does not result in reduced leukemia compared to controls using four separate human Ph- ALL xenografts. [3]

Protocol (from reference)

Cell Research:[1]
  • Cell lines: Immature DCs
  • Concentrations: 10 nM
  • Incubation Time: 4 hours
  • Method: Immature DCs are left intact or are incubated with 2 μM S1P, 10 nM FTY720, 10 nM SEW2871 or the combinations of S1P with these drugs for 4 hours. As a control 1 μg/mL LPS is used. The cells are washed and incubated in a 96-well plate (v-bottom, 2 × 105 cells per well), washed again and resuspended in PBS buffer containing 0.1% sodium azide. They are labeled with 1 μg/mL FITC-conjugated mouse anti-human CD80, 1 μg/mL FITC-conjugated mouse anti-human CD83, 1 μg/mL FITC-conjugated mouse anti-human CD86, 1 μg/mL FITC-conjugated mouse anti-human HLA-class I, 1 μg/mL FITC-conjugated mouse anti-human HLA-DR, 1 μg/mL FITC-conjugated mouse anti-human HLA-E, or 1 μg/mL FITC-conjugated mouse IgG as a control. The cells are washed twice, and examined in the flow cytometer. Markers are set according to the isotype control FITC-conjugated mouse IgG. To stain NK cells with antibodies for various NK cell activating receptors, they are either left untreated or incubated with 2 μM S1P for 4 hours, washed and stained with 1 μg/mL PE-conjugated mouse anti-human NKp30 (CD337), 1 μg/mL PE-conjugated mouse anti-human NKp44 (CD336), 1 μg/mL PE-conjugated mouse anti-human NKG2D (CD314), or as a control 1 μg/mL PE-conjugated mouse IgG1, for 45 min at 4 °C. NK cells are also stained with 1 μg/mL FITC-conjugated anti-killer inhibitory receptor (KIR)/CD158 antibody which recognizes KIR2DL2, KIR2DL3, KIR2DS2 and KIR2DS4, and as a control with FITC-conjugated mouse IgG. The cells are washed twice, and examined in the flow cytometer. Markers are set according to the isotype control PE-conjugated or FITC-conjugated mouse IgG.
Animal Research:[3]
  • Animal Models: NOD/SCIDγc−/− mice bearing ALL cells.
  • Dosages: 5 mg/kg/day, 10 mg/kg/day
  • Administration: Administered via i.p.

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 343.9
Formula

C19H33NO2.HCl

CAS No. 162359-56-0
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05141669 Completed Drug: Fingolimod Multiple Sclerosis Novartis Pharmaceuticals|Novartis May 18 2020 --
NCT03345940 Terminated Drug: Fingolimod|Drug: Dimethyl Fumarate Relapsing Remitting Multiple Sclerosis Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta|Patient-Centered Outcomes Research Institute|Universita degli Studi di Genova April 30 2017 Phase 4
NCT02575365 Terminated Drug: 05 mg Fingolimod Cognition|Brain Volume Loss Novartis Pharmaceuticals|Novartis February 16 2016 Phase 4

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Fingolimod (FTY720) HCl | Fingolimod (FTY720) HCl supplier | purchase Fingolimod (FTY720) HCl | Fingolimod (FTY720) HCl cost | Fingolimod (FTY720) HCl manufacturer | order Fingolimod (FTY720) HCl | Fingolimod (FTY720) HCl distributor